Pfizer Buys Seagen In $43B Enterprise Value Deal
Law 360 M&A
MARCH 13, 2023
Pfizer said Monday it has entered into an agreement to acquire global cancer biotechnology company Seagen for $229 in cash per Seagen share, giving the transaction a total enterprise value of $43 billion.
Let's personalize your content